Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis
DOI:
https://doi.org/10.2340/00015555-3091Keywords:
anti-transcriptional intermediary factor-1? autoantibody, cancer, dermatomyositis, meta-analysisAbstract
Anti-transcriptional intermediary factor-1? (TIF-1?) autoantibody may be associated with cancer in adult patients with dermatomyositis. The aim of this study was to evaluate the risk of cancer in the presence of anti-TIF-1? autoantibody in adult dermatomyositis. A comprehensive database search of EMBASE, MEDLINE and the Cochrane Library up to May 2018 was performed using the main key words ?dermatomyositis?, ??myositis?, ?inflammatory myopathies? and ?anti-TIF-1?. Eighteen studies, with a total of 1,962 dermatomyositis, were included in the meta-analysis. The pooled prevalence of cancer-associated dermatomyositis in patients with anti-TIF-1? autoantibody was 0.41 (95% confidence interval (CI) 0.36?0.45). In the presence of anti-TIF-1? autoantibody, the overall diagnostic odds ratio of cancer was 9.37 (95% CI 5.37?16.34) with low heterogeneity (Cochran?s Q: 14.88 (df?=?17, p?=?0.604); I2?=?0%). The results of this systematic review confirm that detection of anti-TIF-1? autoantibody is a valuable tool to identify a subset of adult dermatomyositis patients with higher risk of cancer.Downloads
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Marion Best, Nicolas Molinari, François Chasset, Thierry Vincent, Nadège Cordel, Didier Bessis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
